MODERNA'S stock soared on Tuesday after the coronavirus vaccine maker reported progress in developing a preventive shot for a deadly form of skin cancer.
The company said a possible melanoma vaccine that it was studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.